Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Respiratory muscle strength study in late-onset Pompe disease
NL-OMON43764Phase 4Not yet recruiting
- Sponsor
- BioMarin Pharmaceutical Inc.
- Start
- Mar 2015
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of reveglucosidase alfa in Pompe disease (2 arms), sponsored by BioMarin Pharmaceutical Inc. Primary endpoint: Comparison of respiratory muscle strength values from volitional versus non-volitional techniques. Planned start Mar 2015; status: not yet recruiting.
02
Drugs
reveglucosidase alfa
03
Conditions
Pompe disease
Beyond the preview
Go deeper on NL-OMON43764.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43764.